First Results of the SONIA Trial are Now Published in Nature – The Netherlands Cancer Institute
The Netherlands Cancer Institute shared on LinkedIn:
โ๐๐ถ๐ฟ๐๐ ๐ฟ๐ฒ๐๐๐น๐๐ ๐ผ๐ณ ๐๐ต๐ฒ ๐ฆ๐ข๐ก๐๐ ๐๐ฟ๐ถ๐ฎ๐น ๐ฎ๐ฟ๐ฒ ๐ป๐ผ๐ ๐ฝ๐๐ฏ๐น๐ถ๐๐ต๐ฒ๐ฑ ๐ถ๐ป ๐ก๐ฎ๐๐๐ฟ๐ฒ.
The prestigious journal Nature published the initial results of the SONIA study today. The study showed that delaying and shortening the duration of treatment with CDK4/6 inhibitors for patients with hormone receptor-positive advanced breast cancer, leads to similar survival outcomes while reducing toxicity and achieving substantial cost savings.
This is the first time an efficiency study like this has been conducted in collaboration with Dutch health insurance providers and the Ministry of Heath, and it highlights the importance of research into the efficient use of medicines for patients, physicians, and policymakers worldwide.
Todayโs publication in Nature underlines the potential of this type of self-funded efficiency research. The SONIA results reaffirm the need for robust sequencing trial data to determine the optimal use of our available therapies. But most importantly, this type of mostly post-marketing academic research can be of great benefit to patients and society, and should be conducted more frequently.
We are very proud to have conducted this study within the Dutch Breast Cancer Cancer Research Group (BOOG Study Center) and in collaboration with the Dutch Breast Cancer Society (BVN), the Netherlands Comprehensive Cancer Organisation (IKNL (Integraal Kankercentrum Nederland)) and the institute for Medical Technology Assessment (iMTA). We want to thank all the patients who have participated in the trial, as well as the study staff throughout all 74 participating hospitals.
We extend a special appreciation to the principal investigators Agnes Jager, Gabe Sonke and Inge Konings, and their PhD students Annemiek van Ommen โ Nijhof and Noor Wortelboer. Last, the study team wants to thank the Netherlands Organization for Health Research (ZonMw) and Development and Dutch Health Insurers (ZN) for funding this trial.โ
Gabe Sonke shared this post on LinkedIn, adding:
โVery grateful to all patients who participated in the SONIA trial and proud of the study team and all participating sites. These results can help to reduce toxicities of CDK4/6 inhibitors in advanced breast cancer and reduce the treatment burden on patients and health care systems.โ
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer | Nature
Authors: Gabe S. Sonke, Annemiek van Ommen-Nijhof, Noor Wortelboer, Vincent van der Noort, Astrid C. P. Swinkels, Hedwig M. Blommestein, Cristina Guerrero Paez, Linda Mol, Aart Beeker, Karin Beelen, Lisanne C. Hamming, Joan B. Heijns, Aafke H. Honkoop, Paul C. de Jong, Quirine C. van Rossum-Schornagel, Christa van Schaik-van de Mheen, Jolien Tol, Cathrien S. Tromp-van Driel, Suzan Vrijaldenhoven, A. Elise van Leeuwen-Stok, Inge R. Konings, Agnes Jager and SONIA Study Consortium
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023